Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Agmatine SCHEMBL28651766 | 0.79 | ALOX15 (0.46) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL31511876 | 0.79 | ALOX15 (0.42) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| Agmatine SCHEMBL4417794 | 0.79 | ALOX15 (0.46) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| Arcaine SCHEMBL303546 | 0.79 | MEN1 (0.62) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| Phosphoric Acid SCHEMBL28436026 | 0.77 | ALOX15 (0.43) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| Phosphoric Acid SCHEMBL29118306 | 0.77 | ALOX15 (0.43) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL3069140 | 0.77 | SMN1; SMN2 (0.67) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL3072659 | 0.77 | SMN1; SMN2 (0.67) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL10728151 | 0.77 | SMN1; SMN2 (0.67) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL11882788 | 0.77 | SMN1; SMN2 (0.67) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183746-A1 | COMPOSITIONS FOR TRANSFER OF CARGO TO CELLS | Sixfold Bioscience Ltd. (GB) | 2023-06-15 | — | — | US | claimed |
| EP-4022058-A2 | COMPOSITIONS FOR TRANSFER OF CARGO TO CELLS | Sixfold Bioscience Ltd. (GB) | 2022-07-06 | — | — | EP | claimed |
| US-12472267-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | Sixfold Bioscience Ltd. (GB) | 2025-11-18 | — | — | US | disclosed |
| US-20230183746-A1 | COMPOSITIONS FOR TRANSFER OF CARGO TO CELLS | Sixfold Bioscience Ltd. (GB) | 2023-06-15 | — | — | US | disclosed |
| EP-4143316-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | Sixfold Bioscience Ltd. (GB) | 2023-03-08 | — | — | EP | disclosed |
| US-20220370635-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | SIXFOLD BIOSCIENCE LTD (GB) | 2022-11-24 | — | — | US | disclosed |
| EP-4022058-A2 | COMPOSITIONS FOR TRANSFER OF CARGO TO CELLS | Sixfold Bioscience Ltd. (GB) | 2022-07-06 | — | — | EP | disclosed |
| US-11357865-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | Sixfold Bioscience Ltd. (GB) | 2022-06-14 | — | — | US | disclosed |
| WO-2021220053-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | Sixfold Bioscience Ltd. (GB) | 2021-11-04 | — | — | WO | disclosed |
| US-20210330810-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | Sixfold Bioscience Ltd. (GB) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11357865-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | NCL, NSUN3, POLN | ALOX15 2891/4885MEN1 890/4885CYP1A2 4848/4885 |
| US-20220370635-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | NCL, NSUN3, POLN | ALOX15 2891/4885MEN1 890/4885CYP1A2 4848/4885 |
| US-20210330810-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | NCL, NSUN3, POLN | ALOX15 2891/4885MEN1 890/4885CYP1A2 4848/4885 |
| US-12472267-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | NCL, NSUN3, POLN | ALOX15 2891/4885MEN1 890/4885CYP1A2 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.